Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA5 | P31644 | 2/20 | 0.33 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.32 |
| ▸ | CFTR | P13569 | 3/20 | 0.31 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.31 |
| ▸ | CSNK1E | P49674 | 2/20 | 0.31 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.31 |
| ▸ | IRAK1 | P51617 | 2/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23700478 | 1.00 | GABRA5 (0.33) | GABRA5PADI4CFTRCSNK1DCSNK1E | |
| SCHEMBL23700479 | 1.00 | GABRA5 (0.33) | GABRA5PADI4CFTRCSNK1DCSNK1E | |
| SCHEMBL23717353 | 0.94 | GABRA5 (0.32) | GABRA5 | |
| SCHEMBL23717354 | 0.94 | GABRA5 (0.32) | GABRA5 | |
| SCHEMBL23700476 | 0.94 | GPR6 (0.32) | GABRA5IRAK4 | |
| SCHEMBL23700475 | 0.94 | GPR6 (0.32) | GABRA5IRAK4 | |
| SCHEMBL23717054 | 0.94 | GABRA5 (0.31) | GABRA5 | |
| SCHEMBL23700474 | 0.94 | GPR6 (0.32) | GABRA5IRAK4 | |
| SCHEMBL23717056 | 0.94 | GABRA5 (0.31) | GABRA5 | |
| SCHEMBL23717569 | 0.92 | GABRA5 (0.33) | GABRA5CFTRCSNK1DCSNK1E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11420976-B2 | Heterocyclic compounds as anti-viral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2022-08-23 | — | — | US | disclosed |
| US-11420976-B2 | Heterocyclic compounds as anti-viral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2022-08-23 | — | — | US | disclosed |
| US-20210238188-A1 | HETEROCYCLIC COMPOUNDS AS ANTI-VIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2021-08-05 | — | — | US | disclosed |
| US-20210238188-A1 | HETEROCYCLIC COMPOUNDS AS ANTI-VIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2021-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238188-A1 | HETEROCYCLIC COMPOUNDS AS ANTI-VIRAL AGENTS | VIP, ACE, FURIN | GABRA5 3187/4885PADI4 1476/4885CFTR 307/4885 |
| US-11420976-B2 | Heterocyclic compounds as anti-viral agents | VIP, ACE, FURIN | GABRA5 3187/4885PADI4 1476/4885CFTR 307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.